Jazz Pharmaceuticals plc (JAZZ) Dividend History
Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid . In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea . In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
Last update 09/19/2023
Dividend Yield Summary
|Date||Amount Per Share||Note|